Vimarsana
Biggest News Aggregation in the World

Page 2 - Multiple Sclerosis Centers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple Sclerosis Centers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple Sclerosis Centers Today - Breaking & Trending Today

Top minds in multiple sclerosis to speak at CMSC 38th Annual Meeting - Vimarsana News

Top minds in multiple sclerosis to speak at CMSC 38th Annual Meeting

The leading research and educational conference for multiple sclerosis healthcare professionals in North America, the Consortium of Multiple Sclerosis Centers (CMSC) 38th Annual Meeting, returns to Nashville, Tennessee, May 29-June 1, 2024 at the Music City Center.

Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to ... - Vimarsana News

Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to ...

-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) --

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS - Vimarsana News

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MSHigh-dose frexalimab significantly reduced dis...

The Language of MS: How Much Does It Matter? - Vimarsana News

The Language of MS: How Much Does It Matter?

The term ‘smoldering MS’ has the blogger Trevis Gleason reflecting on the words used to discuss MS and the meanings they carry.

BTK Inhibitor Evobrutinib Fails to Meet Primary End Points in Phase 3 EVOLUTION Trials - Vimarsana News

BTK Inhibitor Evobrutinib Fails to Meet Primary End Points in Phase 3 EVOLUTION Trials

Results showed that evobrutinib did not produce a more superior reduction in annualized relapse rates than teriflunomide, a previously approved disease-modifying agent.

Source: ajmc.com